Seeking Alpha

AbbVie (ABBV) +4.6% after Morgan Stanley analyst David Risinger upgrades the stock to...

AbbVie (ABBV) +4.6% after Morgan Stanley analyst David Risinger upgrades the stock to "Overweight," citing the company's "under-appreciated pipeline" and other factors. Risinger reckons AbbVie can grab at least 20% of the growing hepatitis C market, and while the analyst maintains his 2013 estimates for the company, he boosts his 2020 EPS forecast to $4.61 from a prior prediction of $2.96.
Comments (2)
  • tomlos
    , contributor
    Comments (1073) | Send Message
     
    Glad we held onto this one post split... Has performed very well!
    22 Apr 2013, 02:36 PM Reply Like
  • gobraves39401
    , contributor
    Comments (420) | Send Message
     
    Tomlos, me to.....Been outperforming ABT.
    23 Apr 2013, 12:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)